Author Affiliations Clinical Research Unit, EFFEGILAB S.r.l., Trento, Italy Received: June 26, 2020 | Published: July 06, 2020 Corresponding author: Fabio Olivieri, Clinical Research Unit, EFFEGILAB S.r.l., Trento, Italy DOI: 10.26717/BJSTR.2020.28.004690 Background and Objectives: The antineoplastic effects of Vitamin E and its derivatives, Tocopherols and Tocotrienols are known in scientific literature [1-3]. In particular, it has been shown that the fractions of Tocotrienol (α, β, γ, δ) are active on different types of cancer, reducing their growth through different pathways [4-6]. Also, Melatonin is known as a molecule capable of regulating the rate of cell growth, with particular activity on cancer cells through different pathways [7-9]. In this study we observed how the dog’s mastocytoma was managed by associating the Delta Tocotrienol with Melatonin conjugated with Adenosine and Glycine. Methods: Eight dogs were treated from May 2018 to June 2019 with Delta Tocotrienol (TOCOTRIENOL FG®) and the Melatonin-Adenosine-Glycine complex (MELATONINA COMPLEX®). The diagnosis in all eight cases was I, II and III-degree mastocytoma with no metastasis. The dogs were tested for biochemical and blood count tests and evaluated clinically every two months. Result: During the treatment period, only one of the dogs with trunk nodule continued to have relapses after surgery, although less frequently than before treatment, and with a slower evolution. None of the patients had been treated with chemotherapy by the owners’ will. Conclusion: Delta Tocotrienol and the Melatonin-Adenosine-Glycine complex allowed the control of tumor development, a reduction of post-surgical recurrences and the total absence of side effects. After a year of treatment, no dog developed mastocytoma again.